Chinese thoracic surgery experts consensus on postoperative follow-up plans for non-small cell lung cancer patients_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LIU Lunxu ¹ , GAO Shugeng ² , HE Jianxing ³ , HU Jian ⁴ , GE Di ⁵ , LI Hecheng ⁶ , KANG Mingqiang ⁷ , TAN Fengwei ² ,  CAI Kaican ⁸ , Chinese Association of Thoracic Surgeons,Thoracic Surgery Society of China Medicine Education Association

1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, P.R.China;
3. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, P.R.China;
4. Department of General Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, P.R.China;
5. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China;
6. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P.R.China;
7. Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P.R.China;
8. Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P.R.China;

Corresponding author：

CAI Kaican, Email: doc_cai@163.com

Keywords：

Non-small cell lung cancer; postoperative follow-up; thoracic surgery; expert consensus

DOI：

10.7507/1007-4848.202010032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Resection is crucial for treating non-small cell lung cancer. Routine follow-up after surgery is an effective method for early detection and treatment of tumor recurrence and metastasis or the second primary tumor, which can improve the quality of life of patients and their prognosis. This consensus aims to provide a reference for colleagues responsible for postoperative follow-up of non-small cell lung cancer patients in China, and further improve the standardization of lung cancer diagnosis and treatment.

Citation： LIU Lunxu, GAO Shugeng, HE Jianxing, HU Jian, GE Di, LI Hecheng, KANG Mingqiang, TAN Fengwei, CAI Kaican. Chinese thoracic surgery experts consensus on postoperative follow-up plans for non-small cell lung cancer patients. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(1): 4-10. doi: 10.7507/1007-4848.202010032 Copy

1.	National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Non-small cell lung cancer, version 8. 2020. https://www.nccn.org/professionals/physician_gls/default.aspx#nscl.
2.	Guideline of Chinese Society of Clinical Oncology (CSCO). Non-small cell lung cancer. 2020. http://www.csco.org.cn/.
3.	Bayarri-Lara CI, de Miguel Pérez D, Cueto Ladrón de Guevara A, et al. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. Eur J Cardiothorac Surg, 2017, 52(1): 55-62.
4.	Cho A, Hur J, Hong YJ, et al. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer. Tumour Biol, 2016, 37(3): 3205-3213.
5.	Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer, 2002, 36(3): 265-270.
6.	Wang L, Wang D, Zheng G, et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers, 2016, 31(1): e80-e87.
7.	Chiu CH, Chern MS, Wu MH, et al. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg, 2003, 125(6): 1300-1305.
8.	Lee JI, Lee YJ, Park KY, et al. Fate of newly detected lesions during postoperative surveillance for non-small cell lung cancer. Ann Thorac Surg, 2013, 95(6): 1867-1871.
9.	Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol, 2020, 38(7): 753-766.
10.	Sánchez de Cos J, Sojo González MA, Montero MV, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer, 2009, 63(1): 140-145.
11.	Xi JJ, Yin JC, Wang L, et al. A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer. J Thorac Dis, 2018, 10(11): 6107-6117.
12.	Toba H, Sakiyama S, Otsuka H, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients. Interact Cardiovasc Thorac Surg, 2012, 15(5): 859-864.
13.	Westeel V, Choma D, Clément F, et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg, 2000, 70(4): 1185-1190.
14.	Mollberg NM, Ferguson MK. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg, 2013, 95(3): 1112-1121.
15.	Hashimoto M, Tanaka F, Yoneda K, et al. Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood (pvCTC) during surgical manipulation in non-small cell lung cancer. J Thorac Dis, 2018, 10(1): 298-306.
16.	Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545(7655): 446-451.
17.	Usui K, Yokoyama T, Naka G, et al. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Jpn J Clin Oncol, 2019, 49(6): 554-558.
18.	张炜, 郭万华. ~(99m)Tc-MDP 全身骨扫描和血清 CEA、NSE、CYFR21-1、CA125 测定对小细胞肺癌骨转移的临床评价. 东南大学学报 (医学版), 2015, 34(6): 881-885.
19.	Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1298-1306.
20.	Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med, 2001, 42(11): 1605-1613.
21.	Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol, 2011, 29(15): 2104-2120.
22.	Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ, 2010, 340: b5569.
23.	郭翠翠. 回顾性分析术后辅助化疗对具有高危因素的ⅠB 期非小细胞肺癌预后的影响. 大连医科大学, 2017.
24.	李冉华. 术后辅助化疗对ⅠB 期非小细胞肺癌预后的影响. 中国医科大学, 2019.
25.	Watanabe K, Tsuboi M, Sakamaki K, et al. Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer. Eur J Cardiothorac Surg, 2016, 49(6): 1624-1631.
26.	Lou F, Sima CS, Rusch VW, et al. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg, 2014, 98(5): 1755-1760.
27.	Subramanian M, Liu J, Greenberg C, et al. Imaging surveillance for surgically resected stage Ⅰ non-small cell lung cancer: Is more always better? J Thorac Cardiovasc Surg, 2019, 157(3): 1205-1217.
28.	Gauger J, Patz EF, Coleman RE, et al. Clinical stage Ⅰ non-small cell lung cancer including FDG-PET imaging: sites and time to recurrence. J Thorac Oncol, 2007, 2(6): 499-505.
29.	Lee K, Kim HR, Kim DK, et al. Post-recurrence survival analysis of stage Ⅰ non-small-cell lung cancer. Asian Cardiovasc Thorac Ann, 2017, 25(9): 623-629.
30.	Mizuno T, Arimura T, Kuroda H, et al. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis, 2018, 10(3): 1788-1796.
31.	Sonobe M, Yamada T, Sato M, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol, 2014, 21(8): 2546-2554.
32.	Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage ⅠA lung adenocarcinoma: wedge resection or segmentectomy. Chest, 2014, 145(1): 66-71.
33.	Li J, Yang X, Xia T, et al. Stage Ⅰ synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis. J Thorac Dis, 2017, 9(12): 5335-5344.
34.	Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 2010, 28(1): 35-42.
35.	Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
36.	Torok JA, Gu L, Tandberg DJ, et al. Patterns of distant metastases after surgical management of non-small-cell lung cancer. Clin Lung Cancer, 2017, 18(1): e57-e70.
37.	Ou W, Sun HB, Ye X, et al. Adjuvant carboplatin-based chemotherapy in resected stage ⅢA-N2 non-small cell lung cancer. J Thorac Oncol, 2010, 5(7): 1033-1041.
38.	McMurry TL, Stukenborg GJ, Kessler LG, et al. More frequent surveillance following lung cancer resection is not associated with improved survival: A nationally representative cohort study. Ann Surg, 2018, 268(4): 632-639.
39.	Ito M, Miyata Y, Tsutani Y, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer, 2020, 141: 107-113.
40.	Xu ST, Xi JJ, Zhong WZ, et al. The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: A post hoc analysis of the ADJUVANT Trial (CTONG 1104). J Thorac Oncol, 2019, 14(3): 503-512.
41.	Ni J, Guo T, Li Y, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res, 2019, 8(6): 967-978.
42.	Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice. J Thorac Oncol, 2018, 13(9): 1373-1382.
43.	Nishino M, Soejima K, Mitsudomi T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res, 2019, 8(Suppl 3): S298-S307.
44.	Mizuno T, Yatabe Y, Kuroda H, et al. Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. Jpn J Clin Oncol, 2016, 46(10): 928-934.
45.	Kim MH, Shim HS, Kang DR, et al. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer, 2014, 83(3): 389-395.
46.	Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol, 2012, 7(1): 90-97.
47.	Shin SH, Lee H, Jeong BH, et al. Anaplastic lymphoma kinase rearrangement in surgically resected stageⅠA lung adenocarcinoma. J Thorac Dis, 2018, 10(6): 3460-3467.
48.	Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res, 2013, 19(16): 4532-4540.
49.	Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage Ⅳ non-small-cell lung cancer. Clin Lung Cancer, 2020, 21(3): e191-e204.
50.	Tong JH, Yeung SF, Chan AW, et al. MET amplification and Exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res, 2016, 22(12): 3048-3056.
51.	Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer, 2018, 123: 76-82.
52.	Ferrara R, Auger N, Auclin E, et al. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol, 2018, 13(1): 27-45.

1. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Non-small cell lung cancer, version 8. 2020. https://www.nccn.org/professionals/physician_gls/default.aspx#nscl.
2. Guideline of Chinese Society of Clinical Oncology (CSCO). Non-small cell lung cancer. 2020. http://www.csco.org.cn/.
3. Bayarri-Lara CI, de Miguel Pérez D, Cueto Ladrón de Guevara A, et al. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. Eur J Cardiothorac Surg, 2017, 52(1): 55-62.
4. Cho A, Hur J, Hong YJ, et al. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer. Tumour Biol, 2016, 37(3): 3205-3213.
5. Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer, 2002, 36(3): 265-270.
6. Wang L, Wang D, Zheng G, et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers, 2016, 31(1): e80-e87.
7. Chiu CH, Chern MS, Wu MH, et al. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg, 2003, 125(6): 1300-1305.
8. Lee JI, Lee YJ, Park KY, et al. Fate of newly detected lesions during postoperative surveillance for non-small cell lung cancer. Ann Thorac Surg, 2013, 95(6): 1867-1871.
9. Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol, 2020, 38(7): 753-766.
10. Sánchez de Cos J, Sojo González MA, Montero MV, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer, 2009, 63(1): 140-145.
11. Xi JJ, Yin JC, Wang L, et al. A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer. J Thorac Dis, 2018, 10(11): 6107-6117.
12. Toba H, Sakiyama S, Otsuka H, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients. Interact Cardiovasc Thorac Surg, 2012, 15(5): 859-864.
13. Westeel V, Choma D, Clément F, et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg, 2000, 70(4): 1185-1190.
14. Mollberg NM, Ferguson MK. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg, 2013, 95(3): 1112-1121.
15. Hashimoto M, Tanaka F, Yoneda K, et al. Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood (pvCTC) during surgical manipulation in non-small cell lung cancer. J Thorac Dis, 2018, 10(1): 298-306.
16. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545(7655): 446-451.
17. Usui K, Yokoyama T, Naka G, et al. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Jpn J Clin Oncol, 2019, 49(6): 554-558.
18. 张炜, 郭万华. ~(99m)Tc-MDP 全身骨扫描和血清 CEA、NSE、CYFR21-1、CA125 测定对小细胞肺癌骨转移的临床评价. 东南大学学报 (医学版), 2015, 34(6): 881-885.
19. Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1298-1306.
20. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med, 2001, 42(11): 1605-1613.
21. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol, 2011, 29(15): 2104-2120.
22. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ, 2010, 340: b5569.
23. 郭翠翠. 回顾性分析术后辅助化疗对具有高危因素的ⅠB 期非小细胞肺癌预后的影响. 大连医科大学, 2017.
24. 李冉华. 术后辅助化疗对ⅠB 期非小细胞肺癌预后的影响. 中国医科大学, 2019.
25. Watanabe K, Tsuboi M, Sakamaki K, et al. Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer. Eur J Cardiothorac Surg, 2016, 49(6): 1624-1631.
26. Lou F, Sima CS, Rusch VW, et al. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. Ann Thorac Surg, 2014, 98(5): 1755-1760.
27. Subramanian M, Liu J, Greenberg C, et al. Imaging surveillance for surgically resected stage Ⅰ non-small cell lung cancer: Is more always better? J Thorac Cardiovasc Surg, 2019, 157(3): 1205-1217.
28. Gauger J, Patz EF, Coleman RE, et al. Clinical stage Ⅰ non-small cell lung cancer including FDG-PET imaging: sites and time to recurrence. J Thorac Oncol, 2007, 2(6): 499-505.
29. Lee K, Kim HR, Kim DK, et al. Post-recurrence survival analysis of stage Ⅰ non-small-cell lung cancer. Asian Cardiovasc Thorac Ann, 2017, 25(9): 623-629.
30. Mizuno T, Arimura T, Kuroda H, et al. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis, 2018, 10(3): 1788-1796.
31. Sonobe M, Yamada T, Sato M, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol, 2014, 21(8): 2546-2554.
32. Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage ⅠA lung adenocarcinoma: wedge resection or segmentectomy. Chest, 2014, 145(1): 66-71.
33. Li J, Yang X, Xia T, et al. Stage Ⅰ synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis. J Thorac Dis, 2017, 9(12): 5335-5344.
34. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 2010, 28(1): 35-42.
35. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
36. Torok JA, Gu L, Tandberg DJ, et al. Patterns of distant metastases after surgical management of non-small-cell lung cancer. Clin Lung Cancer, 2017, 18(1): e57-e70.
37. Ou W, Sun HB, Ye X, et al. Adjuvant carboplatin-based chemotherapy in resected stage ⅢA-N2 non-small cell lung cancer. J Thorac Oncol, 2010, 5(7): 1033-1041.
38. McMurry TL, Stukenborg GJ, Kessler LG, et al. More frequent surveillance following lung cancer resection is not associated with improved survival: A nationally representative cohort study. Ann Surg, 2018, 268(4): 632-639.
39. Ito M, Miyata Y, Tsutani Y, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer, 2020, 141: 107-113.
40. Xu ST, Xi JJ, Zhong WZ, et al. The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: A post hoc analysis of the ADJUVANT Trial (CTONG 1104). J Thorac Oncol, 2019, 14(3): 503-512.
41. Ni J, Guo T, Li Y, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res, 2019, 8(6): 967-978.
42. Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice. J Thorac Oncol, 2018, 13(9): 1373-1382.
43. Nishino M, Soejima K, Mitsudomi T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res, 2019, 8(Suppl 3): S298-S307.
44. Mizuno T, Yatabe Y, Kuroda H, et al. Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. Jpn J Clin Oncol, 2016, 46(10): 928-934.
45. Kim MH, Shim HS, Kang DR, et al. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer, 2014, 83(3): 389-395.
46. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol, 2012, 7(1): 90-97.
47. Shin SH, Lee H, Jeong BH, et al. Anaplastic lymphoma kinase rearrangement in surgically resected stageⅠA lung adenocarcinoma. J Thorac Dis, 2018, 10(6): 3460-3467.
48. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res, 2013, 19(16): 4532-4540.
49. Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage Ⅳ non-small-cell lung cancer. Clin Lung Cancer, 2020, 21(3): e191-e204.
50. Tong JH, Yeung SF, Chan AW, et al. MET amplification and Exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res, 2016, 22(12): 3048-3056.
51. Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer, 2018, 123: 76-82.
52. Ferrara R, Auger N, Auclin E, et al. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol, 2018, 13(1): 27-45.

Previous Article
胰腺癌外科治疗华西10年经验
Next Article
胰腺癌外科治疗华西10年经验

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Chinese thoracic surgery experts consensus on postoperative follow-up plans for non-small cell lung cancer patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content